Manufacturers’ Reliance on R&D Activities to Remain High in Anticoagulants Market
The emergence of online pharmacies is influencing the increasing sales of anticoagulant drugs. Players operating in the anticoagulants market are progressively adopting online sales channels to broaden their reach with low capital investment.
On the demand side, surging incidence of heart attacks, on the backdrop of unhealthy lifestyles adopted by individuals, is projected to widen the patient pool for the anticoagulants market during the forecast period (2020-2026).
The demand for anticoagulants has also recorded a notable growth from developing countries, given the financial support offered by central authorities to revamp healthcare facilities and upgrade service quality.
Sensing high growth prospects of the anticoagulants market, leading players are leveraging research & development activities, which is increasing the number of pipeline drugs.
All-in-all, the anticoagulants market is expected to witness a healthy growth, with an estimated CAGR of ~8% during the forecast period.
Conventional Hold of Warfarin Could Negatively Impact Sales of Anticoagulants
The popularity of conventional drugs such as warfarin is high, especially in developing countries, owing to their cost-benefits. The monthly cost of generic warfarin is in the range of ~US$ 16 t0 ~US$ 20, while that of a monthly supply of NOAC is tantamount to ~US$ 70.
Given this influence, the demand for advanced anticoagulants is likely to get impeded during the forecast period. In addition, these drugs are used for long-term treatment, which requires individuals to allocate an additional budget for these advanced drugs for a long duration.
As a result, individuals residing in India, China, Brazil, and similar developing countries are showing reluctance in buying advanced anticoagulants.
Another aspect that players in the anticoagulants market need to focus on is increasing awareness about the side effects caused by the consumption of NOACs.
Patients undergoing treatment of anticoagulant disorders have reported side effects of NOAC, which include excessive bleeding, vomiting, and nausea. Despite having fewer side effects than conventional drugs, the acceptance of NOAC is low, thereby limiting the growth prospects of the anticoagulants market during the forecast period.
Know More Details About the Report
Patent-Assistance Programs to Underpin Adoption of Anticoagulants
Players in the anticoagulants market are coming forward to shoulder the financial burden of individuals through patient-assistance programs, as an instrument to boost the exposure of anticoagulants.
For instance, Bristol-Myers Squibb offers financial aid to patients to purchase medicines through the company’s foundation. However, the program offers assistance only to individuals who are residents of the U.S. and not insured by any privately- or publicly-held company.
Besides this, Boehringer Ingelheim offers the PRADAXA savings card to buy medicines at minimum rates. Increase in the number of manufacturers taking financial initiatives is projected to boost the adoption of drugs during the forecast period.
Prominence of Heparins to Remain High in Developing Countries of Asia Pacific
In 2020, ~54% of sales of the total North American anticoagulants market are projected to arrive from cases of atrial fibrillation and heart attacks, and factor XA inhibitors will remain the preferred drug class.
On a global level, the U.S. is found to have the highest obesity rate, with Canada occupying a position in the top 10 most obese countries across the world. Given the direct correlation between obesity and heart diseases, the sales of anticoagulants are high in the U.S., and are projected to grow during the forecast period.
The high technological prowess of players operating in the North American anticoagulants market offers them an edge to produce effective drugs with utmost precision, which further accelerates the momentum of the regional market.
In contrast to this, healthcare facilities in Asia Pacific have transformed only recently, which has been drawing the attention of individuals towards the significance of ideal health.
Central authorities and key healthcare organizations are devising guidelines to endorse the use of certain types of drugs to control anticoagulant disorders, which is boosting the growth of the Asia Pacific anticoagulants market.
A shift from conventional heparins to factor XA inhibitors is seen in the developed countries of this region; however, the popularity of heparins is projected to remain high in developing countries during the forecast period.
Avail customized purchase options for your needs
Anticoagulants Market – Assessment of Key Segments
Authors of the report have segmented the anticoagulants market into key categories in order to study the market at a microscopic level. The key segments considered while bifurcating the anticoagulants market include:
|Route of Administration||
Besides laying focus on the aforementioned key segments, the report also studies the anticoagulants market at a country level, to recalibrate the underlying opportunities available for players in the anticoagulants market for the forecast period. Among all the estimated data, the report also includes Y-o-Y growth projections, which can help market players in comprehending the precise trajectory at which the anticoagulants market has been growing.
Anticoagulants Market – Scope of the Study
The study on the anticoagulants market is an exclusive report published by Fact.MR, which highlights the key parameters that are influencing the growth of the landscape. This study offers insights on the growth of the anticoagulants market, by analysing the historical data for the period of 2016-2019, and 2020-2026 as the forecast period.
Estimation of the revenue of the anticoagulants market has been carried out in terms of value (US$ Mn). This research highlights the key trends that hold the potential to influence the growth of the anticoagulants market, along with crucial macroeconomic and microeconomic growth indicators.
This insightful report offers the key dynamics, and their impact on the value chain, which are projected to influence the future growth of the anticoagulants market.
The study also includes a detailed section dedicated to impeders that could challenge the growth of players in the anticoagulants market. The report unfolds lucrative opportunities for market players, which they can leverage to consolidate their position in the global market.
With a view of aiding stakeholders in the anticoagulants market, the study comprises a detailed section on the competition analysis. The study offers a dashboard view of the report, with a comprehensive comparison of players operating in the anticoagulants market, based on total revenue, market presence, and key developments.
Besides this, the recent developments and key strategies of players in the anticoagulants market have also been included in this comprehensive study.
Key companies profiled in this exclusive study include Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Sanofi, and Johnson & Johnson Service.
The study provides crucial insights into the finances of these companies, along with their product portfolios, key strategies, and SWOT analysis. In addition, the study also discusses Porter’s Five Forces, which highlights the threats of substitutes, purchasing power of buyers and suppliers, and intensity of competition present in the anticoagulants market during the forecast period (2020-2026).
Anticoagulants Market – Research Methodology
The anticoagulants market has been evaluated by taking a top-down and bottom-up approach. Demand, geographical presence, distribution strategies by manufacturers, and initiatives taken by governments and NGOs are various factors considered while estimating the revenue of the anticoagulants market, and thus, reaching global numbers.
The study on the anticoagulants market is further validated through extensive primary research on the data extracted from exhaustive secondary research.
In order to conduct secondary research, annual company reports, company websites, data from the World Health Organization (WHO), SEC filings, press releases, investor presentations, and other similar resources were studied. To validate the information compiled through secondary research, interviews with key opinion leaders and subject matter experts were scheduled.
In addition to this, authors of the report also had email and telephonic interactions with the senior management of leading and prominent companies, to confirm the size, growth trend, and future outlook of the anticoagulants market.
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.